求助！高级别b细胞淋巴瘤伴有双打击，应该用哪个方案更好？

接好运好运来！ · 发表于 2025-6-22 13:56:58

请问各位病友，35岁男性患者，确诊为高级别b细胞淋巴瘤伴有双打击，问诊了不同医生，有以下两个选择，请问该选哪一个？
1.pola-r-chp
2.pola+r-epoch
恳请各位病友帮忙分析一下！万分感谢！

来自安卓APP客户端

晚风也温柔 · 发表于 2025-6-22 14:45:19

96

来自安卓APP客户端

晴天-淋巴瘤之家 · 发表于 2025-6-22 15:14:35

第2个

来自安卓APP客户端

接好运好运来！ · 发表于 2025-6-22 16:26:31

晚风也温柔发表于 2025-06-22 14:45
96

感谢回复！

来自安卓APP客户端

接好运好运来！ · 发表于 2025-6-22 16:26:39

晴天-淋巴瘤之家发表于 2025-06-22 15:14
第2个

感谢回复！！

来自安卓APP客户端

妈妈一定CR99 · 发表于 2025-6-22 16:29:42

我们是96小时。

来自安卓APP客户端

梓琳妈妈 · 发表于 2025-6-22 16:33:24

我用的96

来自安卓APP客户端

阳光。 · 发表于 2025-6-23 08:42:51

一看就是同济手机小程序

接好运好运来！ · 发表于 2025-6-23 09:53:52

阳光。发表于 2025-06-23 08:42
一看就是同济手机小程序

您好！请问您家属用的什么治疗方案呢？

来自安卓APP客户端

橙色雨丝 · 发表于 2025-6-23 13:20:39

NCCN指南2025年第2版中，对于双重打击淋巴瘤，无预设条件推荐的方案其实只有一个，那就是DA-EPOCH-R方案。

HGBL with MYC and BCL2 rearrangements with or without BCL6 rearrangements (ICC)
Treatment options
•Clinical trial is recommended.
•Consolidative ISRT is preferred for localized disease.
While the optimal treatment approach is not established, the following induction regimens have been used:
DA-EPOCH-R
RCHOP may be associated with a suboptimal outcome. Could be considered for patients with low risk disease (IPI <2).
R-mini-CHOP may be considered for patients who are frail or older
Potentially toxic regimens; performance status and comorbidities should be considered:
◊R-HyperCVAD
◊R-CODOX-M/R-IVAC

接好运好运来！ · 发表于 2025-6-23 21:27:13

妈妈一定CR99 发表于 2025-06-22 16:29
我们是96小时。

感谢回复！

来自安卓APP客户端

接好运好运来！ · 发表于 2025-6-23 21:27:58

梓琳妈妈发表于 2025-06-22 16:33
我用的96

感谢您的回复！

来自安卓APP客户端

接好运好运来！ · 发表于 2025-6-23 21:28:28

橙色雨丝发表于 2025-06-23 13:20
NCCN指南2025年第2版中，对于双重打击淋巴瘤，无预设条件推荐的方案其实只有一个，那就是DA-EPOCH-R方案。

HGBL with MYC and BCL2 rearrangements with or without BCL6 rearrangements (ICC)
Treatment options
•Clinical trial is recommended.
•Consolidative ISRT is preferred for localized disease.
While the optimal treatment approach is not established, the following induction regimens have been used:
DA-EPOCH-R
RCHOP may be associated with a suboptimal outcome. Could be considered for patients with low risk disease (IPI <2).
R-mini-CHOP may be considered for patients who are frail or older
Potentially toxic regimens; performance status and comorbidities should be considered:
◊R-HyperCVAD
◊R-CODOX-M/R-IVAC

好的，谢谢雨丝大神的回复！

来自安卓APP客户端